-+ 0.00%
-+ 0.00%
-+ 0.00%

OS Therapies Initiates CMAA Process With UK MHRA For Herlystic In Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma; Expects To Complete CMAA Process Later In Q4 Of 2026

Benzinga·11/10/2026 13:19:57
Listen to the news

US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice Meeting

  • Submission expected to be accepted in the fourth quarter of 2026
  • Potential early market access decision expected from MHRA in the first quarter of 2027

Grasonville, Maryland--(Newsfile Corp. - November 10, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has initiated a Conditional Marketing Authorisation Application (CMAA) process with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for Herlystic™ (OST-HER2) in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma. The Company expects to complete the CMAA process later in the fourth quarter of 2026.